Wolfe Research initiated coverage on Arcellx
$ACLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Wolfe Research initiated coverage of Arcellx with a rating of Peer Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2026 | $100.00 | Buy | UBS |
| 12/22/2025 | $100.00 | Overweight | Wells Fargo |
| 11/18/2025 | Peer Perform | Wolfe Research | |
| 10/16/2025 | $129.00 | Buy | Stifel |
| 6/17/2025 | $110.00 | Buy | Citigroup |
| 10/8/2024 | $109.00 | Buy | Redburn Atlantic |
| 9/3/2024 | Overweight | Cantor Fitzgerald | |
| 5/31/2024 | $70.00 | Overweight | Piper Sandler |
SCHEDULE 13G/A - Arcellx, Inc. (0001786205) (Subject)
144 - Arcellx, Inc. (0001786205) (Subject)
S-8 - Arcellx, Inc. (0001786205) (Filer)
UBS resumed coverage of Arcellx with a rating of Buy and set a new price target of $100.00
Wells Fargo initiated coverage of Arcellx with a rating of Overweight and set a new price target of $100.00
Wolfe Research initiated coverage of Arcellx with a rating of Peer Perform
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Arcellx, Inc. (0001786205) (Issuer)
-- CAR constructs representative of anito-cel (D-Domain), cilta-cel (dual VHH), and ide-cel (scFv) were assessed preclinically for tonic signaling and off-target Claudin binding -- -- No tonic signaling or off-target activity was observed with the D-Domain, supporting its unique target-specific binding profile and anito-cel's potentially best-in-class safety profile -- -- Specific off-target activity against Claudin-9 was observed with the dual VHH binder, consistent with cilta-cel's publicly available regulatory assessment reports; the D-Domain and scFv binders did not demonstrate off-target activity -- -- CAR T activation and cytokine release were observed for dual VHH and scFv bind
-- The D-Domain binder has a fast off-rate and contributes to anito-cel's differentiated pharmacology profile in multiple myeloma -- -- A simulation model of CAR T use ahead of bispecific antibodies in 4L+ RRMM is estimated to reduce the risk of progression or death by 64% and death by 48% over five years versus the reverse sequence, supporting CAR T before bispecific antibody as the sequence that delivers superior improved long-term outcomes in 4L+ RRMM -- -- Geographic inequities persist in CAR T access for MM patients marked by long travel, out-of-state care, and bypassed ATCs, highlighting systemic referral gaps and the need for ATC expansion to improve equitable access -- Arcellx
-- Anito-cel demonstrated 96% ORR and 74% CR/sCR at a median follow-up of 15.9 months; responses continue to deepen over time -- -- Overall MRD negativity was 95% and sustained MRD negativity for >6 months was 83%, both at 10-5 sensitivity level -- -- 12-month PFS and OS rates were 82.1% and 94.0%; 18-month PFS and OS rates were 67.4% and 88.0%; 24-month PFS and OS rates were 61.7% and 83.0% -- -- To date, no delayed or non-ICANS neurotoxicities, including no Parkinsonism, no cranial nerve palsies, no Guillain-Barré syndrome, and no immune effector cell-associated enterocolitis have been observed with anito-cel to date; all patients were dosed at least 12 months ago -- -- The company re
SC 13G - Arcellx, Inc. (0001786205) (Subject)
SC 13G/A - Arcellx, Inc. (0001786205) (Subject)
SC 13G/A - Arcellx, Inc. (0001786205) (Subject)
-- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; $100M equity investment; and up to $3.9B in total contingent consideration -- -- Companies to co-commercialize and split profits in the U.S.; Arcellx to receive low to mid-teen royalties outside the U.S. -- -- Arcellx to continue independently progressing its development pipeline and researching new product candidates beyond myeloma -- -- Arcellx to host a conference call and webcast today at 5:45 a.m. PT -- REDWOOD CITY, Calif., and SANTA MONICA, Calif., Dec. 9, 2022 /PRNewswire/ -- Arcellx
-- Mr. Galligan and Ms. Myers bring decades of experience to the company board -- -- Derek Yoon steps down from the Board of Directors -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare industry executive, adds diverse expertise in operational execution, sales and marketing, and market
REDWOOD CITY, Calif., June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Maryam Abdul-Kareem, J.D., as General Counsel. Ms. Abdul-Kareem brings extensive legal and business expertise in the biopharmaceutical industry, including serving in senior positions at Kinnate Biopharma and AstraZeneca. At Arcellx, she will oversee a broad spectrum of legal, contracts, and compliance matters.
FOSTER CITY, Calif., May 23, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Michelle Gilson as Chief Financial Officer. Ms. Gilson joins Arcellx from Canaccord Genuity, where most recently she served as Managing Director and Senior Equity Research Analyst covering biotechnology companies. Ms. Gilson will oversee the company's finance function and will play a key role in overall corporate strategy.